Select Page

AMLThe classification, risk stratification, and treatment landscape in Acute Myeloid Leukemia (AML) have become increasingly complex. Since 2017 numerous drugs have been approved to treat AML, drugs that target genetic mutations (e.g., FLT3; IDH1/2), cell surface antigens (e.g., CD33), or various cell signaling transduction pathways (e.g., hedgehog pathway inhibitors; BCL-2 inhibitors).

Additionally, a variety of different modalities of drugs are currently under investigation in clinical trials for the treatment of patients with AML. These trials include CD47 targeted agents, TIM-3 inhibitors, Bispecific T-Cell Engagers, Menin Inhibitors, MDM2/HDM2 antagonists, and cellular therapies such as CAR-NKs.

Capitalizing on our unique expertise as pioneers of patient chart-based research, we offer subscriptions to our real-world data providing insights and the latest understanding of changing paradigms in the treatment of AML patients, by primary vs type of secondary AML, specific genetic mutations, fitness level, eligibility for IC; HSCT eligibility and much more. Importantly, as the classification system changes, AMLsyndiTrack also captures the physician perceptual classification vs the real-world classification (% myeloblasts) of patients with MDS vs AML-MRC.

Example of recent releases:

  • Data collected in Q4 22 in EU5, USA, Japan and China
  • Back data available for  EU5,  Canada,  Austria,  Switzerland, Belgium, Netherlands, Sweden...
  • over 750 interviews of Onco-Hematologists
  • over 5,600 real-world patient charts analyzed

More information about the AML syndicated study?

  • Objectives
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves

Fill in the form to see a 2-page helicopter view of AMLsyndiTrack with more details on the data collection and a few examples of outputs.



Go further with the data and discover an example of a Digital & Interactive Dashboard (DID) created by APLUSA

We take here the example of a patient share tracker in Cancer X syndiTrackTM.
The dashboard is built around 6 variables: the country, the treatment start date, the treatment line, the product or regimen, risk factors and market share.

In total, there are many advantages of using this DID:
- your data is available online and can be easily shared within your organization,
- you can create your own views instead of manipulating a large number of powerpoint slides,
- you always have the latest data available, no update problems,
- the data is available on your dashboard much earlier in the data collection,
- the report will be more focused on key insights and storytelling than on data production.

👇 Test our live demo here! 👇